Outcomes of 36 vs 38 Hour Intervals From Ovulation Trigger To Oocyte Pick-Up:A Multi-Center Randomized Controlled Trial

Launched by KOÇ UNIVERSITY · Mar 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the best timing for collecting eggs during a fertility treatment called assisted reproduction technology (ART). Specifically, it compares two time intervals—36 hours and 38 hours—between when a woman receives a medication to trigger ovulation and when the eggs are collected. The researchers want to see if waiting longer (38 hours) leads to better outcomes, such as more mature eggs and higher rates of successful fertilization, pregnancy, and live births.

To participate in this study, women must be planning to have ART treatment and be between 18 and 42 years old. They should also be healthy enough to proceed with the treatment and not have certain medical conditions that could affect the results. If eligible, participants will be randomly assigned to one of the two timing groups and will help researchers learn more about how timing may impact the success of fertility treatments. This study aims to improve care for women facing infertility.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • To undergo assisted reproductive technology (ART) treatment and planning to undergo embryo transfer procedure within 6 months of oocyte collection
• • Female partner to be between 18-42 years old at the time of informed consent
• • Both partners to consent to participate in the study and be legally eligible to give consent.
• Exclusion Criteria:
• • Female partner to have participated in the study previously.
• • Female partner to have a body mass index of 35 kg/m2 or above.
• • Female partner to have a systemic disease that may affect ART or pregnancy outcomes (e.g. antiphospholipid syndrome, severe liver dysfunction, diabetes mellitus, history of venous thrombosis, advanced renal or cardiac diseases).
• • Presence of congenital uterine anomaly (1-Women whose uterine anomalies are surgically corrected are not excluded; 2- Arcuate uterus is not accepted as a congenital uterine anomaly).
• • Presence of submucous or intramural fibroid that distorts the endometrial cavity.
• • Diagnosis of stage 3 or 4 endometriosis in the female partner.
• • Female partner planned to undergo double ovarian stimulation.
• • Known karyotype anomaly in at least one of the partners.
• • Diagnosis of azoospermia (no sperm cells in the ejaculate) in the male partner.
• • History of recurrent implantation failure \[defined according to the scoring system by Ata et al in 2021 available at https://bit.ly/3huVLOn (Ata B, Kalafat E, Somigliana E. A new definition of recurrent implantation failure on the basis of anticipated blastocyst aneuploidy rates across female age. Fertil Steril. 2021;116(5):1320-1327. doi:10.1016/j.fertnstert.2021.06.045\].
• • History of recurrent pregnancy loss \[defined as a history of 2 or more biochemical/clinical pregnancy losses, in accordance with the European Society of Human Reproduction and Embryology(ESHRE) Guideline on the management of recurrent pregnancy loss issued on 1 February 2023, available at https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx\].